牛牛AI助理已提取核心訊息
Chewy, Inc. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) on January 18, 2024, to recast certain financial information reflecting the operations of Chewy Pharmacy KY as part of its consolidated financial statements. This follows the transactions with affiliates of BC Partners Advisors LP, which resulted in Chewy Pharmacy KY becoming an indirect wholly-owned subsidiary of Chewy. The recast financial information does not represent a restatement of previously issued financial statements but is intended to reflect the operations of Chewy Pharmacy KY in the company's financials for the fiscal years ended January 30, 2022, and January 29, 2023, as well as the quarterly periods ended April 30, July 30, and October 29, 2023. The report includes both GAAP and certain non-GAAP financial measures, with reconciliations provided for non-GAAP measures. The filing is meant to be read in conjunction with the company's previous reports and other SEC filings.
Chewy, Inc. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) on January 18, 2024, to recast certain financial information reflecting the operations of Chewy Pharmacy KY as part of its consolidated financial statements. This follows the transactions with affiliates of BC Partners Advisors LP, which resulted in Chewy Pharmacy KY becoming an indirect wholly-owned subsidiary of Chewy. The recast financial information does not represent a restatement of previously issued financial statements but is intended to reflect the operations of Chewy Pharmacy KY in the company's financials for the fiscal years ended January 30, 2022, and January 29, 2023, as well as the quarterly periods ended April 30, July 30, and October 29, 2023. The report includes both GAAP and certain non-GAAP financial measures, with reconciliations provided for non-GAAP measures. The filing is meant to be read in conjunction with the company's previous reports and other SEC filings.
Chewy, Inc.已於2024年1月18日向美國證券交易委員會（SEC）提交了8-K表的最新報告，將反映肯塔基州Chewy Pharmacy運營的某些財務信息作爲其合併財務報表的一部分。在此之前，肯塔基州Chewy Parners Advisors LP的關聯公司進行了交易，這導致肯塔基州Chewy Pharmacy成爲Chewy的間接全資子公司。重估的財務信息並不代表先前發佈的財務報表的重述，但旨在在公司截至2022年1月30日和2023年1月29日的財年以及截至2023年4月30日、7月30日和10月29日的季度財務中反映肯塔基州Chewy Pharmacy的運營情況。該報告包括公認會計原則和某些非公認會計准則財務指標，並對非公認會計准則指標進行了對賬。該文件應與該公司先前的報告和其他美國證券交易委員會文件一起閱讀。
Chewy, Inc.已於2024年1月18日向美國證券交易委員會（SEC）提交了8-K表的最新報告，將反映肯塔基州Chewy Pharmacy運營的某些財務信息作爲其合併財務報表的一部分。在此之前，肯塔基州Chewy Parners Advisors LP的關聯公司進行了交易，這導致肯塔基州Chewy Pharmacy成爲Chewy的間接全資子公司。重估的財務信息並不代表先前發佈的財務報表的重述，但旨在在公司截至2022年1月30日和2023年1月29日的財年以及截至2023年4月30日、7月30日和10月29日的季度財務中反映肯塔基州Chewy Pharmacy的運營情況。該報告包括公認會計原則和某些非公認會計准則財務指標，並對非公認會計准則指標進行了對賬。該文件應與該公司先前的報告和其他美國證券交易委員會文件一起閱讀。
有用
沒用